Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag in Chemotherapy-Induced Thrombocytopenia
NCT05261646Phase 3Withdrawn
- Sponsor
- Hengrui
- Start
- Apr 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Hetrombopag with Matching Placebo (2 arms). Primary endpoint: Proportion of treatment responders at 56 days. Planned start Apr 2022; status: withdrawn.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05261646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261646.